Cite

HARVARD Citation

    Larkin, J. et al. (2017). Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. pp. 709-718. [Online]. 
  
Back to record